Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
An observational time and motion study in a clinical oncology setting is utilized in order to measure and compare product attributes and overall product efficiency between lanreotide and octreotide LAR.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| lanreotide group (Somatuline Depot®) | |||
| octreotide LAR group (Sandostatin LAR®) |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| The total time for product preparation and administration | Total drug delivery time | Day 1 |
| Measure | Description | Time Frame |
|---|---|---|
| Total patient wait time for administration | For the purposes of this study, "total patient wait time" refers to the time the patient checks in at the infusion room until completion of drug administration and discharge of the patient from the infusion room. | Day 1 |
| Number of clogging episodes |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Subjects will be recruited through US institutions/clinics that commonly treat neuroendocrine tumor patients.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ipsen Medical Director | Ipsen | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The University of Arizona Cancer Center | Tucson | Arizona | 85719 | United States | ||
| Ochsner Medical Center Kenner |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30924737 | Derived | Ryan P, McBride A, Ray D, Pulgar S, Ramirez RA, Elquza E, Favaro JP, Dranitsaris G. Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis. J Oncol Pharm Pract. 2019 Sep;25(6):1425-1433. doi: 10.1177/1078155219839458. Epub 2019 Mar 29. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The number of clogging episodes for lanreotide and octreotide LAR will be recorded and compared. |
| Day 1 |
| Healthcare resource utilization | The materials used for the preparation of lanreotide and octreotide LAR will be recorded and compared. | Day 1 |
| Pharmacist and/or nurse satisfaction and product preference | Assessed by pharmacist and/or nurse completing questionnaire | Day 1 and at the end of the study (approximately 3 months) |
| Patient satisfaction | Assessed by patient completing questionnaire | Day 1 |
| Kenner |
| Louisiana |
| 70065 |
| United States |
| Mercy Medical Center | Baltimore | Maryland | 21202 | United States |
| National Translational Research Group | East Setauket | New York | 11733 | United States |
| Oncology Specialists of Charlotte | Charlotte | North Carolina | 28207 | United States |
| ID | Term |
|---|---|
| C535650 | Gastro-enteropancreatic neuroendocrine tumor |
Not provided
Not provided
Not provided